AbbVie’s Humira, along with Pfizer’s Lyrica and Xeljanz, each spent more than $25 million on TV advertising for July.
Roche’s Xolair has seen competitors encroach on its territory over the last few years. But now, it’s ready to carve out a new niche of its own.
The FDA has issued a CRL for Regeneron's application to extend the dosing schedule for blockbuster Eylea from eight to 12 weeks.
“Game-changing” is just one way analysts and regulators described Alnylam's approval for RNAi drug Onpattro. But the biotech still has work to do.
Outcome Health, still working to polish its tarnished image, teamed up with Nielsen for the POC industry's first-ever audience measurements.
Salix and US WorldMeds’ launch for first-ever opioid withdrawal drug Lucemyra is tightly focused for now, but they're eyeing the mainstream next.
As Novo Nordisk’s highly anticipated semaglutide nears the market, the company has a big decision to make: How will it price the product?
What do you do when you need growth, and one drug is far and away your biggest? GIve that product as much fuel as possible.
Healthcare reporters questioned a Johnson & Johnson TV ad for anticoagulant treatment Xarelto, calling out potentially "misleading" visuals.
Texas spanked AstraZeneca as a repeat offender in announcing a pair of off-label marketing settlements.
